This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Advanced Non-Squamous NSCLC
Trial Name: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.
Protocol ID: E5508
Cytological or histological confirmation of non-small cell lung cancer.
No prior malignancy with the last 3 years with the exception of superficial melanoma, basal cell carcinoma or carcinoma in situ.
No prior systemic chemotherapy for advanced stage lung cancer.
Prior use of paclitaxel, pemetrexed or bevacizumab is not allowed.Prior use of carboplatin is allowed if it was given as part of adjuvant chemotherapy.
Age > 18 years
Patients with brain mets are not allowed.
Patients must meet required laboratory values.
No history of serious non-healing wounds, ulcers, or bone fractures.
Women must not be pregnant or breast-feeding due to the lack of adequate safety data with the use of bevacizumab and pemetrexed in this group.
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception.
Enrollment: 1282 people will take part in this study at several medical centers.
Taking part in this study may or may not make your health better.While doctors hope that the medications will be more useful against cancer compared to the usual treatment, there is no proof of this yet.We do know that the information from this study will help doctors learn more about maintenance therapy as a treatment for cancer.This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.